Tonix Pharmaceuticals Holding Corp. Q3 2026 Earnings Recap

Tonix shares fell 5.3% after earnings, suggesting investors were not reassured by early launch momentum. While TONMYA sales grew, the launch remains in an early stage, and the transcript points to gross-to-net fluctuations and a newly filed generic challenge as key risks.

Key Takeaways

• TONMYA generated approximately $15 million in third-quarter net sales, up 37% quarter over quarter; management said payer agreements contributed and gross-to-net adjustments were more favorable than expected.
• Prescriptions rose 28% quarter over quarter to 16,375, including 17% growth in new prescriptions and 56% growth in refills. The expanded 150-rep sales force began field work on September 1, with increases across several prescription and writer metrics since then.
• Coverage reached approximately 53% of U.S. covered lives. The company also reported improving prescription approval rates among commercially insured patients and fewer bridge prescriptions.
• Gross-to-net adjustments are expected to fluctuate early in the launch. Separately, Dr. Reddy’s filed an ANDA with a Paragraph IV patent certification for TONMYA; Tonix said it intends to defend its intellectual property.
• Tonix is advancing Phase II programs in major depressive disorder, Lyme disease prevention, and kidney transplant rejection.